{"a":[{"_":"SK strikes settlement with MSN over future Xcopri generic: reports","$":{"href":"/pharma/sk-strikes-patent-infringement-settlement-msn-over-future-blockbuster-xcopri","hreflang":"en"}}]}

PartnershipXcopriPositive

AI Analysis

Summary

SK Biopharmaceuticals reached a patent settlement with India's MSN Laboratories over a generic version of epilepsy drug Xcopri, allowing SK to extend market exclusivity beyond its October 2032 patent expiration date.

Outcome Details

Patent infringement settlement allowing SK Biopharmaceuticals to extend market exclusivity beyond October 2032

Importance:6/10

Sentiment:

0.70

patent settlementgeneric competitionmarket exclusivityepilepsyXcopri

Related Companies

$AGTC $FVNNU $TRAX

Read the original article

Published by FiercePharma on August 19, 2026 11:06 AM

Read Original